Comparative Analysis of Chemotherapy and Immunotherapy in Treating Advanced Cancer
DOI:
https://doi.org/10.56294/hl2025855Keywords:
Chemotherapy, Immunotherapy, Advanced Cancer, Efficacy, Patient OutcomesAbstract
Cancer is still one of the main reasons of death in the world, and treating cancers in their later stages is very hard. Chemotherapy and immunotherapy are the two main ways to treat advanced cancer. They work in different ways and have different benefits and drawbacks. This essay looks at chemotherapy and immunotherapy side by side, comparing how well they work, how safe they are, and how they affect patient results when treating advanced cancers. Chemotherapy is a common treatment that targets cancer cells that divide quickly. This shrinks the growth and stops the disease from getting worse. While chemotherapy has been shown to help some types of cancer, it often comes with serious side effects like weakened immune systems, stomach problems, and hair loss that can make patients' quality of life very bad. Immunotherapy, on the other hand, uses the immune system to find cancer cells and kill them. Immunotherapy, on the other hand, can cause long-lasting recovery by activating immune reactions that target cancer cells, and in some cases, it has fewer side effects. Several methods are used in this method, including immune checkpoint inhibitors, monoclonal antibodies, and cancer medicines. Immunotherapy has shown promise in treating cancers that didn't respond to treatment before, like melanoma, lung cancer, and some types of lymphoma. On the other hand, immunotherapy can cause immune-related side effects like swelling in good organs, which could lead to major problems. This review looks at the most important studies and clinical trials that have compared how well and safely chemotherapy and immunotherapy treat advanced cancer. We look at the rates of reaction, total survival, progression-free survival, and unfavorable events that happen with these different types of treatment. The study also talks about the things that affect the choice of treatment, such as the type of cancer, the patient's health, and their previous treatment history.
References
1. Doki Y, Ajani JA, Kato K, Xu J, Wyrwicz L, Motoyama S, et al. Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma. N Engl J Med. 2022;386(5):449-62. Available from: https://doi.org/10.1056/NEJMoa2111380
2. Puhr HC, Prager GW, Ilhan-Mutlu A. How we treat esophageal squamous cell carcinoma. ESMO Open. 2023;8(1):100789. Available from: https://doi.org/10.1016/j.esmoop.2022.100789
3. Sun JM, Shen L, Shah MA, Enzinger P, Adenis A, Doi T, et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. Lancet. 2021;398(10302):759-71. Available from: https://doi.org/10.1016/S0140-6736(21)01234-4
4. Obermannová R, Alsina M, Cervantes A, Leong T, Lordick F, Nilsson M, et al. Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(10):992-1004. Available from: https://doi.org/10.1016/j.annonc.2022.07.003
5. Xu J, Lu D, Zhang L, Li J, Sun G. Palliative resection or radiation of primary tumor prolonged survival for metastatic esophageal cancer. Cancer Med. 2019;8(16):7253-64. Available from: https://doi.org/10.1002/cam4.2583
6. Li T, Lv J, Li F, Diao P, Wang J, Li C, et al. Prospective Randomized Phase 2 Study of Concurrent Chemoradiation Therapy (CCRT) Versus Chemotherapy Alone in Stage IV Esophageal Squamous Cell Carcinoma (ESCC). Int J Radiat Oncol Biol Phys. 2016;96(2):S1. Available from: https://doi.org/10.1016/j.ijrobp.2016.06.005
7. Chen Y, Cheng X, Song H, Wu AJ, Ku GY, Lee P, et al. Outcomes of concurrent chemoradiotherapy versus chemotherapy alone for esophageal squamous cell cancer patients presenting with oligometastases. J Thorac Dis. 2019;11(4):1536-45. Available from: https://doi.org/10.21037/jtd.2019.03.51
8. Moreno AC, Zhang N, Giordano S, Komaki RU, Liao Z, Nguyen QN, et al. Comparative Effectiveness of Chemotherapy Alone Versus Chemotherapy and Radiation Therapy for Patients with Stage IV Esophageal Cancer. Int J Radiat Oncol Biol Phys. 2017;99(2):E172-3. Available from: https://doi.org/10.1016/j.ijrobp.2017.06.824
9. Wada Y, Anbai A, Takagi N, Kumagai S, Okuyama E, Nanjo H, et al. Outcomes of Definitive Chemoradiotherapy for Stage IVa (T4b vs. N4) Esophageal Squamous Cell Carcinoma Based on the Japanese Classification System: A Retrospective Single-Center Study. Cancers. 2020;13(1):8. Available from: https://doi.org/10.3390/cancers13010008
10. Ishida K. Phase II Study of Cisplatin and 5-Fluorouracil with Concurrent Radiotherapy in Advanced Squamous Cell Carcinoma of the Esophagus: A Japan Esophageal Oncology Group (JEOG)/Japan Clinical Oncology Group Trial (JCOG9516). Jpn J Clin Oncol. 2004;34(10):615-9. Available from: https://doi.org/10.1093/jjco/hyh109
11. Chen B, Deng M, Yang C, Dragomir MP, Zhao L, Bai K, et al. High incidence of esophageal fistula on patients with clinical T4b esophageal squamous cell carcinoma who received chemoradiotherapy: A retrospective analysis. Radiother Oncol. 2021;158:191-9. Available from: https://doi.org/10.1016/j.radonc.2021.02.024
12. Makino T, Yamasaki M, Tanaka K, Miyazaki Y, Takahashi T, Kurokawa Y, et al. Treatment and clinical outcome of clinical T4 esophageal cancer: A systematic review. Ann Gastroenter Surg. 2019;3(2):169-80. Available from: https://doi.org/10.1002/ags3.12225
13. Zhu S, Zhang T, Zheng L, Liu H, Song W, Liu D, et al. Combination strategies to maximize the benefits of cancer immunotherapy. J Hematol Oncol. 2021;14(1):156. Available from: https://doi.org/10.1186/s13045-021-01164-5
14. Liu P, Chen J, Zhao L, Hollebecque A, Kepp O, Zitvogel L, et al. PD-1 blockade synergizes with oxaliplatin-based, but not cisplatin-based, chemotherapy of gastric cancer. Oncoimmunology. 2022;11(1):2093518. Available from: https://doi.org/10.1080/2162402X.2022.2093518
15. Kroemer G, Galassi C, Zitvogel L, Galluzzi L. Immunogenic cell stress and death. Nat Immunol. 2022;23(4):487-500. Available from: https://doi.org/10.1038/s41590-022-01132-2
16. Zitvogel L, Pitt JM, Daillere R, Smyth MJ, Kroemer G. Mouse models in oncoimmunology. Nat Rev Cancer. 2016;16(12):759-73. Available from: https://doi.org/10.1038/nrc.2016.91
17. Ma Y, Adjemian S, Mattarollo SR, Yamazaki T, Aymeric L, Yang H, et al. Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells. Immunity. 2013;38(4):729-41. Available from: https://doi.org/10.1016/j.immuni.2013.03.003
18. Limagne E, Thibaudin M, Nuttin L, Spill A, Derangere V, Fumet JD, et al. Trifluridine/Tipiracil plus Oxaliplatin Improves PD-1 Blockade in Colorectal Cancer by Inducing Immunogenic Cell Death and Depleting Macrophages. Cancer Immunol Res. 2019;7(12):1958-69. Available from: https://doi.org/10.1158/2326-6066.CIR-19-0228
19. Li Y, Zhang H, Li Q, Zou P, Huang X, Wu C, et al. CDK12/13 inhibition induces immunogenic cell death and enhances anti-PD-1 anticancer activity in breast cancer. Cancer Lett. 2020;495:12-21. Available from: https://doi.org/10.1016/j.canlet.2020.09.011
20. Fukushima H, Yoshida S, Kijima T, Nakamura Y, Fukuda S, Uehara S, et al. Combination of Cisplatin and Irradiation Induces Immunogenic Cell Death and Potentiates Postirradiation Anti-PD-1 Treatment Efficacy in Urothelial Carcinoma. Int J Mol Sci. 2021;22(2):535. Available from: https://doi.org/10.3390/ijms22020535
21. Shan CK, Du YB, Zhai XT, Wang YX, Li Y, Gong JH, et al. Pingyangmycin enhances the antitumor efficacy of anti-PD-1 therapy associated with tumor-infiltrating CD8+ T cell augmentation. Cancer Chemother Pharmacol. 2021;87(3):425-36. Available from: https://doi.org/10.1007/s00280-020-04194-w
22. Yamazaki T, Buque A, Ames TD, Galluzzi L. PT-112 induces immunogenic cell death and synergizes with immune checkpoint blockers in mouse tumor models. Oncoimmunology. 2020;9(1):1721810. Available from: https://doi.org/10.1080/2162402X.2020.1721810
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Pragati Aniket Manoli, Rashmi Gudur, Jatin Khurana, Aakash Sharma, Pramod Reddy (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
The article is distributed under the Creative Commons Attribution 4.0 License. Unless otherwise stated, associated published material is distributed under the same licence.
